The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 08, 2026

Filed:

Feb. 14, 2022
Applicant:

Astellas Pharma Inc., Tokyo, JP;

Inventors:

Kenichi Kawaguchi, Tokyo, JP;

Kazuyuki Kuramoto, Tokyo, JP;

Tomoyoshi Imaizumi, Tokyo, JP;

Takahiro Morikawa, Tokyo, JP;

Mitsuaki Okumura, Tokyo, JP;

Sunao Imada, Tokyo, JP;

Eiji Kawaminami, Tokyo, JP;

Ryo Sato, Tokyo, JP;

Yohei Seki, Tokyo, JP;

Hisao Hamaguchi, Tokyo, JP;

Hiroki Ishioka, Tokyo, JP;

Hiroki Fukudome, Tokyo, JP;

Ikumi Kuriwaki, Tokyo, JP;

Takeyuki Nagashima, Tokyo, JP;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 487/08 (2006.01); A61P 35/00 (2006.01); C07D 519/00 (2006.01);
U.S. Cl.
CPC ...
C07D 487/08 (2013.01); A61P 35/00 (2018.01); C07D 519/00 (2013.01);
Abstract

[Problem] A compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer is provided. [Solution] The present inventors have studied about a compound that is useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer and have found that a 4-aminoquinazoline compound has an excellent G12D mutant KRAS inhibition activity and can be used as a therapeutic agent for pancreatic cancer, thus completing the present invention. The 4-aminoquinazoline compound of the present invention or a salt thereof can be used as a therapeutic agent for pancreatic cancer.


Find Patent Forward Citations

Loading…